Earnings

Intuitive Surgical Stock Holds Above $400 as Analysts Split Ahead of Q2 Earnings

Intuitive Surgical (ISRG) closed at $404.70, barely above its 52-week low, as analysts hold mixed views ahead of Q2 earnings on July 16. High volume from FTSE Russell rebalancing adds pressure on the $400 support level.

James Calloway · · · 2 min read · 9 views
Intuitive Surgical Stock Holds Above $400 as Analysts Split Ahead of Q2 Earnings
Mentioned in this article
ISRG $404.70 +1.25%

Intuitive Surgical (NASDAQ:ISRG) ended the week at $404.70, a 1.25% gain on Friday, but the stock remains under pressure as it hovers just 2% above its 52-week low. The robotic surgery leader has lost nearly 33% from its January high of $603.88, and analysts are split on whether the current valuation reflects realistic earnings expectations.

Key Support Test Ahead

Shares closed Friday at $404.70, with a weekly gain of only 0.43%. The stock traded in a tight range between $398.89 and $412.54, reflecting investor caution. The next major test will be the $400 support level, especially after Friday's surge in trading volume to 3.41 million shares—47% above the 65-day average—driven by FTSE Russell's semi-annual index reconstitution.

The FTSE Russell rebalancing, which took effect after the market close on June 26, is expected to generate about $150 billion in trading activity. Jefferies analyst Steven DeSanctis called it a "really massive trade" with "dramatic" turnover, while Stephens analyst Melissa Roberts described Friday as a "key liquidity day."

Analyst Outlook Divided

Wall Street remains cautious but not bearish. The median analyst target is $575.50, implying a 42% upside from Friday's close. However, the lowest target is $366, below the current price. Of 25 analysts tracked by FactSet, 19 rate the stock as "buy," five as "overweight," and one as "sell."

Q2 EPS estimates stand at $2.51, unchanged from last month, while the full-year 2026 EPS forecast is $10.45, up from $10.05 three months ago. The stock trades at about 38.7 times forward earnings, a premium that reflects growth expectations but also leaves little room for disappointment.

Q1 Performance and Tariff Concerns

In Q1, Intuitive reported worldwide da Vinci and Ion procedure growth of 17%, revenue of $2.77 billion (up 23%), and non-GAAP EPS of $2.50. CEO Dave Rosa cited "expanded adoption" of the company's platforms. However, the 2026 outlook includes da Vinci procedure volume growth of 13.5% to 15.5% and non-GAAP gross margin of 67.5% to 68.5%, with a 1.0% revenue hit from tariffs already factored in. CFO Jamie Samath warned that additional tariffs could have a material impact.

Market Context

The broader market added to the pressure, with the S&P 500 falling 2% and the Nasdaq dropping 4.6% last week as AI-related stocks declined. The Dow Jones Industrial Average rose 0.6%. U.S. markets will close early on July 3 for Independence Day, and Intuitive's next major event is its Q2 earnings call on July 16 at 1:30 p.m. PDT.

Investors are now watching whether the stock can hold above $400 once the rebalancing-related volume subsides. If it does, it may signal that the market has priced in enough pessimism. If not, the gap between price and analyst targets could widen further.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →